Sobi (OM:SOBI) Stock May Be Fully Priced After A CTCL Licensing Deal
Swedish Orphan Biovitrum has delivered a strong share price run over the past five years. However, its current market multiples screen as overvalued, and broader valuation checks point to a stock that is not obviously cheap. For investors, that mix raises the question of how much of the company’s recent progress and pipeline activity is already reflected in today’s price.
- Swedish Orphan Biovitrum has returned 155.5% over the past five years, which puts a clear spotlight on whether the current valuation leaves much room for error.
- The recent licensing deal for lacutamab in cutaneous T cell lymphoma can support expectations for future revenue, while the planned CEO transition in early 2027 may add some uncertainty to how that growth is executed and valued.
- The company only passes 2 of 6 valuation checks, which leans more toward Swedish Orphan Biovitrum looking expensive than like a clear bargain on the current numbers.
The issue now is whether Swedish Orphan Biovitrum’s current share price still offers an attractive entry point after such a strong multi year run.
Is Swedish Orphan Biovitrum Getting Expensive on Earnings?
The P/E ratio is a useful metric for Swedish Orphan Biovitrum because earnings are a key anchor for how investors value profitable biopharma stocks. Swedish Orphan Biovitrum currently trades on a P/E of about 110.9x. This level is well above the broader Biotechs industry average of 27.2x and also above the peer group average of around 76.3x.
The fair P/E ratio implied by the model is 50.3x, which is less than half of where Swedish Orphan Biovitrum trades today. This gap indicates that, given its current earnings profile and risk factors, the stock carries a relatively high earnings multiple. While the recent lacutamab licensing deal in cutaneous T cell lymphoma may support sentiment, the market is already assigning a premium price to Swedish Orphan Biovitrum’s earnings.
On the P/E multiple, Swedish Orphan Biovitrum currently appears expensive relative to the model’s indication.
See what the numbers say about this price — find out in our valuation breakdown.
The Swedish Orphan Biovitrum Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the valuation puzzle for Swedish Orphan Biovitrum leaves off. They spell out which assumptions about Swedish Orphan Biovitrum's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and sit on the company’s Community page. Each one presents fair value as a thesis about the business that you can watch over time rather than a one off snapshot.
Community views on Swedish Orphan Biovitrum sit far apart, with one camp seeing meaningful upside potential and another focused on valuation risk.
Bull case: 23% undervalued
"The company is in an unusually dense launch cycle, with 6 high-value medicines expected on the market by 2028 and multiple programs such as NASP, Tryngolza and Arthrosi’s late-stage gout asset moving toward regulatory decisions and submissions…"
Read the full Bull Case to see why Swedish Orphan Biovitrum could be undervalued
Bear case: 40% overvalued
"The planned launch of six high-value medicines by 2028 requires heavy development and commercial spending, and if any of these programs are delayed, fail to gain approval or launch more slowly than expected, the current revenue base may not be sufficient to justify today’s valuation…"
Read the full Bear Case to see why Swedish Orphan Biovitrum could be overvalued
Do you think there's more to the story for Swedish Orphan Biovitrum? Head over to our Community to see what others are saying!
The Bottom Line
For Swedish Orphan Biovitrum, the current market multiples suggest the stock is priced on the expensive side rather than as a clear bargain. The valuation work so far points to a lot of optimism already reflected in the P/E multiple, with only limited support from broader checks. The key question from here is whether Swedish Orphan Biovitrum can deliver the growth, margins and execution around its launch pipeline that would keep investors comfortable paying this kind of premium over time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com